CL2021000516A1 - Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) - Google Patents

Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)

Info

Publication number
CL2021000516A1
CL2021000516A1 CL2021000516A CL2021000516A CL2021000516A1 CL 2021000516 A1 CL2021000516 A1 CL 2021000516A1 CL 2021000516 A CL2021000516 A CL 2021000516A CL 2021000516 A CL2021000516 A CL 2021000516A CL 2021000516 A1 CL2021000516 A1 CL 2021000516A1
Authority
CL
Chile
Prior art keywords
antibodies
tau
encode
fragments
vector
Prior art date
Application number
CL2021000516A
Other languages
English (en)
Inventor
Malcolm Ian Roberts
James Martin Staddon
Silva Hettihewage Alfred Rohan De
Jared Spidel
Hirofumi Aoyagi
Shigeru Akasofu
Yutaka Hashizume
Kishan Agarwala
Original Assignee
Eisai R&D Man Co Ltd
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Ucl Business Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2021000516A1 publication Critical patent/CL2021000516A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas.
CL2021000516A 2017-10-16 2021-03-02 Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) CL2021000516A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572910P 2017-10-16 2017-10-16
US201762577011P 2017-10-25 2017-10-25
US201862697034P 2018-07-12 2018-07-12

Publications (1)

Publication Number Publication Date
CL2021000516A1 true CL2021000516A1 (es) 2021-09-24

Family

ID=64100697

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020001003A CL2020001003A1 (es) 2017-10-16 2020-04-15 Anticuerpos anti-tau y uso de los mismos.
CL2021000517A CL2021000517A1 (es) 2017-10-16 2021-03-02 Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CL2021000516A CL2021000516A1 (es) 2017-10-16 2021-03-02 Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2020001003A CL2020001003A1 (es) 2017-10-16 2020-04-15 Anticuerpos anti-tau y uso de los mismos.
CL2021000517A CL2021000517A1 (es) 2017-10-16 2021-03-02 Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)

Country Status (20)

Country Link
US (4) US10829547B2 (es)
EP (1) EP3697814A1 (es)
JP (2) JP6851549B2 (es)
KR (2) KR20200058480A (es)
CN (1) CN111630064B (es)
AU (1) AU2018352308A1 (es)
BR (1) BR112020007536A2 (es)
CA (1) CA3077247A1 (es)
CL (3) CL2020001003A1 (es)
CO (1) CO2020005981A2 (es)
IL (2) IL273832B (es)
JO (1) JOP20200074A1 (es)
MA (1) MA50397A (es)
MX (1) MX2020003857A (es)
PE (2) PE20210115A1 (es)
PH (1) PH12020550243A1 (es)
SG (1) SG11202003392VA (es)
TW (3) TWI750419B (es)
WO (1) WO2019077500A1 (es)
ZA (1) ZA202001548B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
HUE060258T2 (hu) 2016-05-02 2023-02-28 Prothena Biosciences Ltd Tau immunterápia
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
JOP20200074A1 (ar) * 2017-10-16 2020-04-30 Eisai R&D Man Co Ltd أجسام مضادة ضد tau واستخداماتها
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN116096751A (zh) * 2020-02-25 2023-05-09 璟尚生物制药公司 三特异性t细胞接合器
US20220064271A1 (en) * 2020-09-01 2022-03-03 Washington University Methods for treating tauopathies
EP4367516A1 (en) 2021-07-09 2024-05-15 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
AU2022381556A1 (en) 2021-11-03 2024-05-02 Eisai R&D Management Co., Ltd. Anti-tau antibody compositions, dosage forms, and methods
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023111618A1 (en) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023114586A1 (en) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
TW202339794A (zh) 2022-02-02 2023-10-16 日商衛材R&D企管股份有限公司 使用ｐ—ｔａｕ１８１水平之治療方法
WO2024118665A1 (en) 2022-11-28 2024-06-06 Eisai R&D Management Co., Ltd. Methods of treatment using a tau pet level

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN105732813A (zh) 2007-12-18 2016-07-06 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EA032675B1 (ru) 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
AU2011311516B2 (en) 2010-10-07 2015-06-11 Ac Immune S.A. Phosphospecific antibodies recognising Tau
NZ609984A (en) 2010-10-11 2015-05-29 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
KR20140051840A (ko) 2011-03-11 2014-05-02 라모트 앳 텔-아비브 유니버시티 리미티드 신경변성 타우오패씨를 치료하는 방법
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
AU2012311234B2 (en) * 2011-09-19 2017-09-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
UA114902C2 (uk) 2011-12-20 2017-08-28 Янссен Байотек, Інк. Виділене антитіло, яке зв'язує парний спіральний філамент-тау (псф-тау), та фармацевтична композиція, що містить таке антитіло
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
US20150183854A1 (en) 2012-05-31 2015-07-02 Teijin Pharma Limited Therapeutic agent or prophylactic agent for dementia
MY171473A (en) 2012-07-03 2019-10-15 Univ Washington Antibodies to tau
CA2882034C (en) 2012-08-16 2019-10-29 Ipierian, Inc. Methods of treating a tauopathy
WO2014059442A2 (en) 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014089104A1 (en) 2012-12-03 2014-06-12 Washington University Method for detection of aggregates in biological samples
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
JP6568514B2 (ja) 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
PL3007726T3 (pl) 2013-06-10 2021-01-11 Ipierian, Inc. Metody leczenia tauopatii
GB201312226D0 (en) 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
DK3083680T3 (da) 2013-12-20 2020-03-16 Hoffmann La Roche Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
WO2015170528A1 (ja) 2014-05-07 2015-11-12 株式会社村田製作所 弾性表面波装置
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
BR112016030183A2 (pt) * 2014-06-26 2017-11-14 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
RU2020126237A (ru) 2014-11-19 2020-12-01 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
AU2015353585A1 (en) 2014-11-25 2017-06-01 Abbott Diabetes Care Inc. Analyte monitoring systems and related test and monitoring methods
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
CA2977648C (en) 2015-02-24 2024-01-02 Rpeptide, Llc Anti-tau antibodies
JO3576B1 (ar) * 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
MA44955A (fr) 2015-06-05 2019-03-20 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
AU2016289755C1 (en) 2015-07-06 2021-08-19 UCB Biopharma SRL Tau-binding antibodies
EP3319984A1 (en) 2015-07-06 2018-05-16 UCB Biopharma SPRL Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US9704904B2 (en) * 2015-08-27 2017-07-11 Taiwan Semiconductor Manufacturing Company, Ltd. Deep trench isolation structures and methods of forming same
US20190194345A1 (en) 2015-10-05 2019-06-27 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
CA3027561A1 (en) 2016-07-12 2018-01-18 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
BR112019022906A2 (pt) * 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
JOP20200074A1 (ar) 2017-10-16 2020-04-30 Eisai R&D Man Co Ltd أجسام مضادة ضد tau واستخداماتها

Also Published As

Publication number Publication date
KR20200058480A (ko) 2020-05-27
CL2020001003A1 (es) 2020-10-02
KR102225178B1 (ko) 2021-03-10
CN111630064A (zh) 2020-09-04
CL2021000517A1 (es) 2021-09-24
MX2020003857A (es) 2021-01-08
US10829547B2 (en) 2020-11-10
JP2020536534A (ja) 2020-12-17
CA3077247A1 (en) 2019-04-25
KR20200051035A (ko) 2020-05-12
RU2020115817A3 (es) 2022-04-08
JP2021097698A (ja) 2021-07-01
PH12020550243A1 (en) 2021-02-15
TW202207985A (zh) 2022-03-01
ZA202001548B (en) 2021-10-27
TWI750419B (zh) 2021-12-21
JP6851549B2 (ja) 2021-03-31
IL290783A (en) 2022-04-01
US10358485B2 (en) 2019-07-23
TWI809562B (zh) 2023-07-21
IL273832B (en) 2022-06-01
SG11202003392VA (en) 2020-05-28
IL273832A (en) 2020-05-31
US20210024622A1 (en) 2021-01-28
BR112020007536A2 (pt) 2020-09-29
CO2020005981A2 (es) 2020-07-31
EP3697814A1 (en) 2020-08-26
CN111630064B (zh) 2023-06-27
US11578120B2 (en) 2023-02-14
PE20210115A1 (es) 2021-01-19
RU2020115817A (ru) 2021-11-18
US20240034777A1 (en) 2024-02-01
US20190112364A1 (en) 2019-04-18
JP7223794B2 (ja) 2023-02-16
TW202340244A (zh) 2023-10-16
AU2018352308A1 (en) 2020-03-19
TW201927817A (zh) 2019-07-16
US20190112365A1 (en) 2019-04-18
MA50397A (fr) 2020-08-26
JOP20200074A1 (ar) 2020-04-30
WO2019077500A1 (en) 2019-04-25
PE20212088A1 (es) 2021-11-04

Similar Documents

Publication Publication Date Title
CL2021000516A1 (es) Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
AR109276A1 (es) ANTICUERPOS ANTI-hCTLA 4
CL2020002269A1 (es) Anticuerpo que se une a redil33; polinucleótido; vector; célula hospedadora; método para producir el anticuerpo; composición farmacéutica; producto de combinación; uso del anticuerpo para tratar una afección inflamatoria (divisional de la solicitud no. 201702433)
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
AR115389A1 (es) Anticuerpo antagonista de cd73
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
CL2019001434A1 (es) Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946)
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CL2017002705A1 (es) Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
CL2021002389A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296)
CL2021002168A1 (es) Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407).